Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms

Rhea-AI Summary

Exousia Pro (OTCID:LMMY) executed an exclusive, worldwide license with the University of Central Florida for patented and patent-pending exosome technologies for cancer diagnosis and therapy.

Key assets include a U.S. patent (US011193174B2, granted Dec 7, 2021) for Exosomal NANOG DNA as a diagnostic marker, and a patent-pending exosomal delivery platform with filings in the U.S., Canada, China, Europe, and Japan. The licensed diagnostic aims to be a non-invasive, single multi-cancer screening using 2 ml saliva and PCR processing to detect rare, late-presenting “silent killer” cancers. Exousia Pro plans two subsidiaries: Exousia Health to commercialize the NANOG screening test and a majority-owned sub-licensee to operate as Exousia Bio (OTCID:LMMY) for therapy applications.

Positive

• Exclusive worldwide license to UCF exosome IP including US patent US011193174B2
• Diagnostic requires only 2 ml saliva using PCR for rapid, non-invasive screening
• Patent filings pending in U.S., Canada, China, Europe, and Japan

Negative

• Therapeutic platform remains patent-pending in key jurisdictions (not yet granted)
• No clinical performance or validation data for the NANOG screening test disclosed

ORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced the execution of an exclusive licensing agreement between its wholly owned subsidiary, Exousia Pro Holding Management, LLC, and the University of Central Florida (UCF) concerning its groundbreaking technology for both the diagnosis and treatment of cancer using exosomes.

Securing Foundational, Worldwide Intellectual Property

The agreement grants Exousia Pro Holding Management (EPHM) an exclusive license to UCF-developed patented and patent-pending intellectual property. This robust intellectual property portfolio includes:

1. Exosomal NANOG DNA as a Diagnostic Cancer Marker: This key technology is protected by a U.S. Patent (US011193174B2) granted on December 7, 2021, focusing on the use of Exosomal NANOG DNA for cancer screening.

2. Exosomal Delivery Platform for Therapy: A comprehensive system for the delivery of gene expression modulating agents for therapy against cancer and viral infection, with patent applications pending across multiple critical jurisdictions, including the U.S., Canada, China, Europe, and Japan.

This exclusive, global licensing strategy ensures Exousia Pro maintains a dominant position over foundational technologies essential for developing next-generation exosome-based diagnostics and therapeutics.

Game-Changing Diagnostic Potential: Detecting Rare Silent Killer Cancers

The licensed technology incorporates the development of a proprietary NANOG DNA cancer screening test. This test is positioned as a game-changing, non-invasive diagnostic tool with the ability to detect a wide spectrum of cancers, including rare, highly aggressive malignancies often referred to as "silent killer" cancers due to their late-stage presentation.

The test offers several competitive advantages in the field of liquid biopsy:

• Universal Screening: The test is designed as a single, multi-cancer screening tool, eliminating the need for separate tests for different cancer types.

• High Sensitivity and Specificity: The assay measures Exosomal NANOG DNA, a potent biomarker, and is not influenced by external factors such as medications or co-existing health ailments, providing exceptional reliability.

• Non-Invasive and Efficient: Requiring only a minimal 2 ml saliva sample, the test uses Polymerase Chain Reaction (PCR) processing to provide rapid, scalable results, lowering barriers to early detection.

Exousia Pro plans to create a new subsidiary, Exousia Health, to manage the commercialization of this crucial cancer screening test under a sub-license agreement with EPHM. Furthermore, a separate sub-license will be granted to its majority-owned subsidiary, LAMY, to become Exousia Bio, Inc. (OTCID:LMMY), for cancer-therapy applications.

Executive Commentary

"The formal execution of this exclusive agreement with the University of Central Florida culminates eleven months of intensive negotiations and represents a major, foundational milestone for the Company," stated Matt Dwyer, President of Exousia Pro, Inc. "This license is absolutely critical to the success of leveraging NANOG in cancer therapy and ensures that we are positioned to benefit from future potential pharmaceutical partnerships. Crucially, it provides us with the rights to a diagnostic tool, the NANOG DNA screening test, and the potential to be the first non-invasive diagnostic capable of detecting rare, silent killer cancers at an early, actionable stage."

About Exousia Pro, Inc.

Exousia Pro, Inc. (EXO), through its subsidiary Exousia Pro Holding Management, is a biotechnology company advancing proprietary technologies. Its focus is on utilizing exosomes for nucleic acid loading and targeted delivery to tissues and cells, alongside developing highly sensitive assays for measuring NANOG DNA as a universal cancer screening test.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Exousia Pro, Inc.
www.Exousiapro.com
X: @Exousia_Pro

Investor Relations
ir@exousiapro.com

SOURCE: Exousia Pro, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Exousia Pro announce on December 2, 2025 regarding LMMY?

Exousia Pro announced an exclusive, worldwide license from University of Central Florida for exosome-based cancer diagnostic and therapy technologies.

What patent covers Exousia Pro's NANOG cancer diagnostic (LMMY)?

The diagnostic is covered by U.S. patent US011193174B2, granted on December 7, 2021.

How does the Exousia Pro NANOG screening test work and what sample is required?

The test measures Exosomal NANOG DNA from a 2 ml saliva sample and uses PCR for analysis.

Will Exousia Pro commercialize the NANOG test through a new unit?

Yes, the company plans to create Exousia Health to manage commercialization under a sub-license.

Are the therapy delivery patents for LMMY fully granted worldwide?

No; the exosomal delivery platform has patent applications pending across multiple jurisdictions.

Does the press release include clinical validation data for the screening test?

No; the announcement does not disclose clinical performance or validation metrics.